NO20016007D0 - Rekombinant anti-CD40-antistoff og anvendelser derav - Google Patents

Rekombinant anti-CD40-antistoff og anvendelser derav

Info

Publication number: NO20016007D0
Authority: NO; Norway
Prior art keywords: antibody; recombinant anti; methods; binding; potentiates
Prior art date: 1999-06-08

Application number

NO20016007A

Other languages

English (en)

Other versions

NO20016007L (no

Inventor

Clay B Siegall

Alan F Wahl

Joseph A Francisco

Jr Henry P Fell

Original Assignee

Seatle Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-08

Filing date

2001-12-07

Publication date

2001-12-07

2001-12-07 Application filed by Seatle Genetics Inc filed Critical Seatle Genetics Inc

2001-12-07 Publication of NO20016007D0 publication Critical patent/NO20016007D0/no

2002-01-28 Publication of NO20016007L publication Critical patent/NO20016007L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20016007A 1999-06-08 2001-12-07 Rekombinant anti-CD40-antistoff og anvendelser derav NO20016007L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/328,296 US6946129B1 (en)	1999-06-08	1999-06-08	Recombinant anti-CD40 antibody and uses thereof
PCT/US2000/015749 WO2000075348A1 (en)	1999-06-08	2000-06-08	Recombinant anti-cd40 antibody and uses thereof

Publications (2)

Publication Number	Publication Date
NO20016007D0 true NO20016007D0 (no)	2001-12-07
NO20016007L NO20016007L (no)	2002-01-28

Family

ID=23280379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20016007A NO20016007L (no)	1999-06-08	2001-12-07	Rekombinant anti-CD40-antistoff og anvendelser derav

Country Status (18)

Country	Link
US (8)	US6946129B1 (no)
EP (1)	EP1190074B1 (no)
JP (1)	JP2003519470A (no)
KR (2)	KR20090088929A (no)
CN (1)	CN1369015A (no)
AT (1)	ATE519501T1 (no)
AU (1)	AU784313B2 (no)
BR (1)	BR0011394A (no)
CA (1)	CA2376485C (no)
HK (1)	HK1049500A1 (no)
HU (1)	HUP0301789A2 (no)
IL (2)	IL146950A0 (no)
MX (1)	MXPA01012614A (no)
NO (1)	NO20016007L (no)
NZ (1)	NZ516250A (no)
PL (1)	PL363995A1 (no)
WO (1)	WO2000075348A1 (no)
ZA (1)	ZA200110215B (no)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050255106A1 (en) *	1999-05-22	2005-11-17	Linda Diehl	Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
US6946129B1 (en) *	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
KR20020072277A (ko) *	1999-11-08	2002-09-14	아이덱 파마슈티칼즈 코포레이션	항-ｃｄ20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-ｃｄ40ｌ 항체를 이용한 ｂ세포 악성종양의치료방법
BR0108001A (pt) *	2000-02-01	2004-01-06	Tanox Inc	Moléculas ativadoras de apc com ligação para cd-40
CN102206277A (zh)	2000-02-10	2011-10-05	雅培制药有限公司	结合人白介素-18的抗体及制备和使用方法
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
CA2410371C (en)	2000-06-22	2015-11-17	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
EP1326896B1 (en)	2000-10-02	2010-11-24	Novartis Vaccines and Diagnostics, Inc.	Human anti-cd40 antibodies
ATE507839T1 (de) *	2001-04-02	2011-05-15	Genentech Inc	Kombinationstherapie
EP2009027B1 (en) *	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
EP1392359B2 (en)	2001-05-11	2013-03-13	Ludwig Institute for Cancer Research Ltd.	Specific binding proteins and uses thereof
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20080199471A1 (en) *	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
KR100788093B1 (ko)	2002-04-26	2007-12-21	제넨테크, 인크.	단백질의 비친화성 정제
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
EP1844815B1 (en)	2003-11-04	2011-09-14	Novartis Vaccines and Diagnostics, Inc.	Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
EP2149585B1 (en)	2003-11-04	2013-08-14	Novartis Vaccines and Diagnostics, Inc.	Use of antagonistic anti-CD40 monoclonal antibodies
ATE476991T1 (de)	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
ATE474599T1 (de)	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
EP2243491A1 (en)	2003-11-04	2010-10-27	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
EP1707627B1 (en) *	2003-12-25	2012-11-14	Kyowa Hakko Kirin Co., Ltd.	Antagonistic anti-CD40 antibody mutant
US20050287121A1 (en) *	2004-05-12	2005-12-29	Merchiers Pascal G	Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7655229B2 (en)	2004-09-02	2010-02-02	Chan Andrew C	Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en)	2004-09-02	2010-02-16	Genentech, Inc.	Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
TW200714289A (en) *	2005-02-28	2007-04-16	Genentech Inc	Treatment of bone disorders
US8067546B2 (en)	2005-04-19	2011-11-29	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
US8333970B2 (en)	2005-05-18	2012-12-18	Novartis Ag	Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease
CA2609269C (en) *	2005-05-26	2014-08-05	Seattle Genetics, Inc.	Humanized anti-cd40 antibodies and their methods of use
US8735157B2 (en)	2005-06-09	2014-05-27	Gal Markel	CEACAM1 mediated protective immunity
KR20080073725A (ko) *	2005-11-01	2008-08-11	노파르티스 아게	항-ｃｄ40 항체의 용도
RU2442606C2 (ru) *	2005-11-01	2012-02-20	Новартис Аг	Применение анти-cd40-антител
JP2009518441A (ja) *	2005-12-09	2009-05-07	シアトルジェネティクス，インコーポレーテッド	Ｃｄ４０結合剤の使用方法
GB0525214D0 (en)	2005-12-12	2006-01-18	Bioinvent Int Ab	Biological materials and uses thereof
NZ571757A (en)	2006-04-21	2012-01-12	Novartis Ag	Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
MX2008013993A (es) *	2006-05-03	2009-05-11	Univ Colorado	Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular.
FR2902799B1 (fr)	2006-06-27	2012-10-26	Millipore Corp	Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US20090074711A1 (en) *	2006-09-07	2009-03-19	University Of Southhampton	Human therapies using chimeric agonistic anti-human cd40 antibody
GB0620894D0 (en) *	2006-10-20	2006-11-29	Univ Southampton	Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
ES2523915T5 (es)	2006-12-01	2022-05-26	Seagen Inc	Agentes de unión a la diana variantes y usos de los mismos
US8569464B2 (en)	2006-12-21	2013-10-29	Emd Millipore Corporation	Purification of proteins
US8163886B2 (en)	2006-12-21	2012-04-24	Emd Millipore Corporation	Purification of proteins
US8362217B2 (en)	2006-12-21	2013-01-29	Emd Millipore Corporation	Purification of proteins
KR101431856B1 (ko)	2007-01-22	2014-08-27	제넨테크, 인크.	항체의 고분자전해질 침전 및 정제
EP2125893A2 (en) *	2007-01-23	2009-12-02	Xencor, Inc.	Optimized cd40 antibodies and methods of using the same
ES2609094T3 (es)	2007-01-25	2017-04-18	Dana-Farber Cancer Institute, Inc.	Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
JP5618549B2 (ja)	2007-03-15	2014-11-05	ルードヴィッヒインスティテュートフォーキャンサーリサーチリミテッド	Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
KR102055873B1 (ko)	2007-07-09	2019-12-13	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
MX2010001757A (es)	2007-08-14	2010-09-14	Ludwig Inst Cancer Res	Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
CA2704499C (en)	2007-11-07	2020-03-10	Genentech, Inc.	Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CA2712989C (en)	2008-01-23	2015-10-27	Xencor, Inc.	Optimized cd40 antibodies and methods of using the same
US8999702B2 (en)	2008-06-11	2015-04-07	Emd Millipore Corporation	Stirred tank bioreactor
US8961991B2 (en) *	2009-03-10	2015-02-24	Baylor Research Institute	Anti-CD40 targeted fusion proteins
PT2848625T (pt)	2008-08-14	2019-10-25	Genentech Inc	Métodos para remover um contaminante com a utilização de cromatografia de membrana de permuta iónica de deslocação de proteína indígena.
CN102227447A (zh)	2008-10-02	2011-10-26	新兴产品开发西雅图有限公司	Cd86拮抗物多靶点结合蛋白
US20110286916A1 (en) *	2008-11-20	2011-11-24	Jose Miguel Aste-Amezaga	Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
SG171446A1 (en)	2008-12-16	2011-07-28	Millipore Corp	Stirred tank reactor and method
DK2396036T3 (en)	2009-02-13	2017-10-16	Immunomedics Inc	Immune conjugates with an intracellular cleavable compound
ES2547712T3 (es)	2009-02-27	2015-10-08	Genentech, Inc.	Métodos y composiciones para el marcado de proteínas
CA3032548C (en)	2009-03-10	2023-05-09	Baylor Research Institute	Anti-cd40 antibodies and uses thereof
CA2754764A1 (en) *	2009-03-10	2010-09-16	Baylor Research Institute	Antigen presenting cell targeted cancer vaccines
US9617600B2 (en)	2009-04-18	2017-04-11	Genentech, Inc.	Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
KR20180010324A (ko)	2009-08-11	2018-01-30	제넨테크, 인크.	글루타민-비함유 세포 배양 배지에서의 단백질의 생성
SI2473617T1 (sl)	2009-09-01	2020-07-31	F. Hoffmann-La Roche Ag	Izboljšano prečiščevanje beljakovin z modificirano elucijo beljakovine A
EP3009455A1 (en)	2009-09-16	2016-04-20	Immunomedics Inc.	Class i anti-cea antibodies and uses thereof
IN2012DN03354A (no)	2009-12-02	2015-10-23	Immunomedics Inc
US20120309056A1 (en)	2010-02-04	2012-12-06	Leon Arnaud	Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
RU2584232C2 (ru)	2010-03-22	2016-05-20	Дженентек, Инк.	Композиции и способы, используемые для стабилизации белоксодержащих готовых форм
BR112012027828A2 (pt)	2010-05-03	2016-08-09	Genentech Inc	composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
KR101726707B1 (ko)	2010-05-17	2017-04-13	이엠디 밀리포어 코포레이션	생체분자 정제용 자극 반응성 중합체
MX374851B (es)	2010-05-28	2025-03-06	Genentech Inc	Disminuir nivel de lactato e incrementar produccion de polipeptidos por regulacion a la baja de la expresion de lactato dehidrogenasa y piruvato dehidrogenasa quinasa
WO2012030512A1 (en)	2010-09-03	2012-03-08	Percivia Llc.	Flow-through protein purification process
WO2012075111A1 (en)	2010-11-30	2012-06-07	Novartis Ag	Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
HUE065915T2 (hu)	2011-03-11	2024-06-28	Beth Israel Deaconess Medical Ct Inc	Anti-CD40 antitestek és alkalmazásaik
US8778345B2 (en)	2011-04-29	2014-07-15	Apexigen, Inc.	Anti-CD40 antibodies
CN103501825B (zh)	2011-05-02	2017-03-15	免疫医疗公司	用于小体积施用的同种异型选择的抗体的超滤浓缩
GB201115280D0 (en) *	2011-09-05	2011-10-19	Alligator Bioscience Ab	Antibodies, uses and methods
NZ756727A (en)	2011-10-28	2022-12-23	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof
MX360453B (es)	2011-12-22	2018-11-01	Genentech Inc	Cromatografia de membrana de intercambio ionico.
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2017139267A (ru)	2012-03-27	2019-02-12	Дженентек, Инк.	Усовершенствованные способы выделения рекомбинантных белков
HRP20250525T1 (hr)	2012-05-18	2025-06-20	Genentech, Inc.	Visokokoncentrirane formulacije monoklonskog protutijela
CN111499684B (zh)	2012-06-19	2024-10-22	Ambrx公司	抗cd70抗体药物结合物
CN104428315B (zh)	2012-07-13	2017-09-29	罗氏格黎卡特股份公司	双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
EP2885002A4 (en)	2012-08-14	2016-04-20	Ibc Pharmaceuticals Inc	BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
CN110066335B (zh)	2012-10-30	2024-04-05	埃派斯进有限公司	抗-cd40抗体及其使用方法
WO2017004144A1 (en)	2015-07-01	2017-01-05	Immunomedics, Inc.	Antibody-sn-38 immunoconjugates with a cl2a linker
JP6366111B2 (ja)	2012-12-13	2018-08-01	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬
US9393327B2 (en)	2012-12-19	2016-07-19	Genentech, Inc.	Methods and compositions for radiohalogen protein labeling
JP6286532B2 (ja)	2013-04-29	2018-02-28	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
US11117975B2 (en)	2013-04-29	2021-09-14	Teva Pharmaceuticals Australia Pty Ltd	Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CN106103483A (zh)	2014-01-13	2016-11-09	贝勒研究院	抗hpv和hpv相关的疾病的新疫苗
AU2015219495B2 (en)	2014-02-21	2019-11-21	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
US9139649B2 (en)	2014-02-25	2015-09-22	Immunomedics, Inc.	Humanized anti-CD22 antibody
UA119352C2 (uk)	2014-05-01	2019-06-10	Тева Фармасьютикалз Острейліа Пті Лтд	Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2015200260A1 (en)	2014-06-24	2015-12-30	Immunomedics, Inc.	Anti-histone therapy for vascular necrosis in severe glomerulonephritis
WO2016007752A1 (en)	2014-07-09	2016-01-14	Genentech, Inc.	Ph adjustment to improve thaw recovery of cell banks
EP3954373A1 (en)	2014-10-07	2022-02-16	Immunomedics, Inc.	Neoadjuvant use of antibody-drug conjugates
EP3831847A1 (en)	2014-10-29	2021-06-09	Seagen Inc.	Dosage and administration of non-fucosylated anti-cd40 antibodies
EP3212216A4 (en)	2014-10-29	2018-04-18	Teva Pharmaceuticals Australia Pty Ltd	Interferon alpha2b variants
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN107709365A (zh)	2015-04-13	2018-02-16	戊瑞治疗有限公司	癌症组合疗法
CN107428837A (zh)	2015-04-22	2017-12-01	免疫医疗公司	循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
PT3313443T (pt)	2015-06-25	2023-08-30	Immunomedics Inc	Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
WO2017009843A2 (en)	2015-07-16	2017-01-19	Biokine Therapeutics Ltd.	Compositions, articles of manufacture and methods for treating cancer
WO2017040380A2 (en)	2015-08-28	2017-03-09	Research Development Foundation	Engineered antibody fc variants
KR20250007054A (ko)	2015-09-04	2025-01-13	프리마토프 테라퓨틱스 인크.	인간화 항-cd40 항체 및 그의 용도
JP2018529351A (ja)	2015-09-30	2018-10-11	ヤンセンバイオテツク，インコーポレーテツド	ヒトｃｄ４０に特異的に結合するアンタゴニスト抗体及び使用方法
JP7208492B2 (ja)	2016-03-10	2023-01-19	シージーオンコロジー，インコーポレイテッド	併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
EP3436610A1 (en)	2016-03-29	2019-02-06	Geltor, Inc.	Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
WO2017184619A2 (en)	2016-04-18	2017-10-26	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human cd40 and uses thereof
CA3025347A1 (en) *	2016-05-27	2017-11-30	Abbvie Biotherapeutics Inc.	Anti-cd40 antibodies and their uses
EP3471754A1 (en)	2016-06-20	2019-04-24	Kymab Limited	Anti-pd-l1 antibodies
MX2018015853A (es)	2016-07-14	2019-08-21	Genmab As	Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
CN109790220A (zh)	2016-08-25	2019-05-21	豪夫迈·罗氏有限公司	与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh)	2016-12-22	2023-09-15	豪夫迈·罗氏有限公司	在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
EP3558366A1 (en)	2016-12-22	2019-10-30	H. Hoffnabb-La Roche Ag	Methods and formulations for reducing reconstitution time of lyophilized polypeptides
IL268593B2 (en)	2017-02-10	2025-05-01	Genmab Bv	Polypeptides and antibodies having increased cdc and/or agonistic activity and their uses in medicine
KR102364599B1 (ko)	2017-04-04	2022-02-21	에프. 호프만-라 로슈 아게	Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
AU2018271915B2 (en)	2017-05-24	2025-03-27	Als Therapy Development Institute	Therapeutic anti-CD40 ligand antibodies
BR112019025048A2 (pt)	2017-06-01	2020-06-30	Jiangsu Hengrui Medicine Co., Ltd.	anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
US11180541B2 (en)	2017-09-28	2021-11-23	Geltor, Inc.	Recombinant collagen and elastin molecules and uses thereof
CA3103629A1 (en)	2018-06-15	2019-12-19	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
PL3818078T3 (pl)	2018-07-03	2024-04-29	Bristol-Myers Squibb Company	Metody produkcji białek rekombinowanych
MY203902A (en)	2018-10-01	2024-07-23	Hoffmann La Roche	Bispecific antigen binding molecules comprising anti-fap clone 212
EP3860653A1 (en)	2018-10-05	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
US12415980B2 (en)	2018-10-10	2025-09-16	Boehringer Ingelheim International Gmbh	Method for membrane gas transfer in high density bioreactor culture
SG11202103064YA (en)	2018-10-29	2021-05-28	Hoffmann La Roche	Antibody formulation
US20240254248A1 (en)	2018-11-30	2024-08-01	Jiangsu Hengrui Medicine Co., Ltd.	Cd40 antibody pharmaceutical composition and use thereof
AU2019389354A1 (en)	2018-11-30	2021-07-15	Jiangsu Hengrui Medicine Co., Ltd.	Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
CN111548415B (zh) *	2019-03-04	2021-04-20	北京天广实生物技术股份有限公司	与cd40特异结合的抗体及其用途
KR20220004985A (ko) *	2019-03-27	2022-01-12	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	Cd40 활성화 특성을 가진 재조합 단백질
SG11202111349QA (en)	2019-04-12	2021-11-29	Geltor Inc	Recombinant elastin and production thereof
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
TW202206100A (zh)	2020-04-27	2022-02-16	美商西健公司	癌症之治療
CA3184366A1 (en)	2020-06-29	2022-01-06	Darby Rye Schmidt	Viruses engineered to promote thanotransmission and their use in treating cancer
CN116194570A (zh)	2020-09-22	2023-05-30	百时美施贵宝公司	用于产生治疗性蛋白的方法
WO2022072523A1 (en)	2020-09-30	2022-04-07	Seagen Inc.	Uveal melanoma treatment using sea-cd40
EP4240415A1 (en)	2020-11-08	2023-09-13	Seagen Inc.	Combination-therapy antibody drug conjugate with immune cell inhibitor
CN112409486B (zh) *	2020-11-26	2022-05-20	杭州百凌生物科技有限公司	一种抗cd40抗体及其应用
FI4284512T3 (fi)	2021-01-28	2025-05-22	Regeneron Pharma	Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
CA3206549A1 (en)	2021-01-29	2022-08-04	Frederick G. Vogt	Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
MX2023010512A (es)	2021-03-09	2023-12-08	Genmab As	Agentes de union multiespecificos contra cd40 y cd137 en terapia.
US20250073349A1 (en)	2021-05-10	2025-03-06	Kawasaki Institute Of Industrial Promotion	Antibody having reduced binding affinity for antigen
EP4370552A1 (en)	2021-07-13	2024-05-22	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4377348A1 (en)	2021-07-30	2024-06-05	Seagen Inc.	Treatment for cancer
WO2023049687A1 (en)	2021-09-21	2023-03-30	Bristol-Myers Squibb Company	Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
US12234294B2 (en)	2021-11-05	2025-02-25	Kiniksa Pharmaceuticals, Gmbh	Pharmaceutical composition of a humanized anti-CD40 antibody
WO2023147488A1 (en)	2022-01-28	2023-08-03	Iovance Biotherapeutics, Inc.	Cytokine associated tumor infiltrating lymphocytes compositions and methods
US20250249278A1 (en)	2022-04-14	2025-08-07	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
CA3258884A1 (en)	2022-06-10	2023-12-14	Research Development Foundation	Modified FCRIIB Selective FC IGG1 Variants and Their Uses
WO2024118836A1 (en)	2022-11-30	2024-06-06	Iovance Biotherapeutics, Inc.	Processes for production of tumor infiltrating lymphocytes with shortened rep step
EP4626446A1 (en)	2022-12-01	2025-10-08	BioNTech SE	Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025093035A1 (en) *	2023-11-03	2025-05-08	Utc Therapeutics (Shanghai) Co., Ltd.	Cd40-targetting antibodies and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182368A (en)	1986-06-13	1993-01-26	Ledbetter Jeffrey A	Ligands and methods for augmenting B-cell proliferation
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
IL84285A (en)	1986-10-27	1993-03-15	Int Genetic Engineering	Chimeric antibody with specificity to human tumor antigen
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
US6657103B1 (en)	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) *	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5872215A (en) *	1991-12-02	1999-02-16	Medical Research Council	Specific binding members, materials and methods
DE69333082T2 (de)	1992-02-11	2004-05-06	Cell Genesys, Inc., Foster City	Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
US5874082A (en) *	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
AU5098493A (en) *	1992-08-21	1994-03-15	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en)	1992-09-04	1996-07-30	Bristol-Myers Squibb Company	Soluble and its use in B cell stimulation
US5985847A (en) *	1993-08-26	1999-11-16	The Regents Of The University Of California	Devices for administration of naked polynucleotides which encode biologically active peptides
DK0724456T3 (da) *	1993-10-01	2004-04-13	Immunex Corp	CD40-Antistoffer
US5597569A (en) *	1993-10-25	1997-01-28	Bristol-Myers Squibb Company	Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica
NZ278740A (en)	1993-12-23	1998-05-27	Immunex Corp	Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
GB9425060D0 (en)	1994-12-13	1995-02-08	Univ Birmingham	Carcinoma treatment
US6037454A (en)	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
US6558671B1 (en) *	1997-01-30	2003-05-06	The University Of Virginia Patent Foundation	Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
WO1998058678A1 (en) *	1997-06-20	1998-12-30	Tanox Pharma B.V.	Anti-cd40l immunotoxins for the treatment of diseases
US6051228A (en) *	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
ES2249907T3 (es)	1998-05-23	2006-04-01	Leiden University Medical Center	Anticuerpos de union cd40 y peptidos ctl para el tratamiento de tumores.
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
EP1803730A1 (en)	2000-04-12	2007-07-04	Human Genome Sciences, Inc.	Albumin fusion proteins
SI2357006T1 (sl)	2002-07-31	2016-01-29	Seattle Genetics, Inc.	Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
US7596539B2 (en) *	2003-05-29	2009-09-29	International Business Machines Corporation	Method and apparatus for providing connection information of functional components within a computer system
US20050136055A1 (en)	2003-12-22	2005-06-23	Pfizer Inc	CD40 antibody formulation and methods
US7213446B2 (en) *	2004-08-27	2007-05-08	Semmaterials, L.P.	Method of selecting a bituminous emulsion based on its coalescence
CA2609269C (en)	2005-05-26	2014-08-05	Seattle Genetics, Inc.	Humanized anti-cd40 antibodies and their methods of use
JP2009518441A (ja)	2005-12-09	2009-05-07	シアトルジェネティクス，インコーポレーテッド	Ｃｄ４０結合剤の使用方法

1999
- 1999-06-08 US US09/328,296 patent/US6946129B1/en not_active Expired - Lifetime
2000
- 2000-06-08 CN CN00811357A patent/CN1369015A/zh active Pending
- 2000-06-08 WO PCT/US2000/015749 patent/WO2000075348A1/en not_active Ceased
- 2000-06-08 IL IL14695000A patent/IL146950A0/xx unknown
- 2000-06-08 MX MXPA01012614A patent/MXPA01012614A/es active IP Right Grant
- 2000-06-08 EP EP00939679A patent/EP1190074B1/en not_active Expired - Lifetime
- 2000-06-08 PL PL00363995A patent/PL363995A1/xx not_active Application Discontinuation
- 2000-06-08 HU HU0301789A patent/HUP0301789A2/hu unknown
- 2000-06-08 KR KR1020097013741A patent/KR20090088929A/ko not_active Ceased
- 2000-06-08 CA CA2376485A patent/CA2376485C/en not_active Expired - Lifetime
- 2000-06-08 BR BR0011394-8A patent/BR0011394A/pt not_active Application Discontinuation
- 2000-06-08 AT AT00939679T patent/ATE519501T1/de not_active IP Right Cessation
- 2000-06-08 NZ NZ516250A patent/NZ516250A/en unknown
- 2000-06-08 JP JP2001501630A patent/JP2003519470A/ja active Pending
- 2000-06-08 AU AU54731/00A patent/AU784313B2/en not_active Ceased
- 2000-06-08 HK HK03101596.3A patent/HK1049500A1/zh unknown
- 2000-11-28 US US09/724,409 patent/US6838261B1/en not_active Expired - Lifetime
- 2000-11-28 US US09/724,530 patent/US6843989B1/en not_active Expired - Lifetime
2001
- 2001-12-06 IL IL146950A patent/IL146950A/en not_active IP Right Cessation
- 2001-12-07 NO NO20016007A patent/NO20016007L/no not_active Application Discontinuation
- 2001-12-08 KR KR1020017015848A patent/KR100917262B1/ko not_active Expired - Fee Related
- 2001-12-12 ZA ZA200110215A patent/ZA200110215B/en unknown
2004
- 2004-05-14 US US10/846,981 patent/US7498032B2/en not_active Expired - Fee Related
- 2004-08-16 US US10/919,923 patent/US20050008637A1/en not_active Abandoned
2005
- 2005-04-08 US US11/102,743 patent/US7510711B2/en not_active Expired - Fee Related
2009
- 2009-01-20 US US12/356,511 patent/US7666422B2/en not_active Expired - Fee Related
- 2009-12-28 US US12/648,108 patent/US7824683B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100917262B1 (ko)	2009-09-16
US7824683B2 (en)	2010-11-02
US6838261B1 (en)	2005-01-04
US7498032B2 (en)	2009-03-03
ZA200110215B (en)	2004-01-21
IL146950A0 (en)	2002-08-14
US7666422B2 (en)	2010-02-23
HK1049500A1 (zh)	2003-05-16
US20050266002A1 (en)	2005-12-01
WO2000075348A1 (en)	2000-12-14
US20100158906A1 (en)	2010-06-24
CA2376485A1 (en)	2000-12-14
PL363995A1 (en)	2004-11-29
EP1190074B1 (en)	2011-08-10
CA2376485C (en)	2011-09-20
EP1190074A4 (en)	2005-06-01
US20040235074A1 (en)	2004-11-25
US7510711B2 (en)	2009-03-31
KR20090088929A (ko)	2009-08-20
NZ516250A (en)	2005-09-30
US20050008637A1 (en)	2005-01-13
CN1369015A (zh)	2002-09-11
NO20016007L (no)	2002-01-28
MXPA01012614A (es)	2003-09-04
US6843989B1 (en)	2005-01-18
AU5473100A (en)	2000-12-28
IL146950A (en)	2009-06-15
US6946129B1 (en)	2005-09-20
US20090280117A1 (en)	2009-11-12
EP1190074A1 (en)	2002-03-27
KR20020026453A (ko)	2002-04-10
HUP0301789A2 (hu)	2003-09-29
ATE519501T1 (de)	2011-08-15
JP2003519470A (ja)	2003-06-24
BR0011394A (pt)	2004-06-08
AU784313B2 (en)	2006-03-09

Publication	Publication Date	Title
NO20016007D0 (no)	2001-12-07	Rekombinant anti-CD40-antistoff og anvendelser derav
MY137552A (en)	2009-02-27	Methods for treating rheumatic diseases using a soluble ctla4 molecule
SG127739A1 (en)	2006-12-29	Use of immuno-regulators
WO2003043583A3 (en)	2004-09-16	Treatment of immunological disorders using anti-cd30 antibodies
MXPA05010830A (es)	2005-12-15	Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
ATE513563T1 (de)	2011-07-15	Therapeutische und toleranz-induzierende antikörper
BG110703A (en)	2010-10-29	PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
IL195328A0 (en)	2009-08-03	Antibodies binding to anionic phospholipids and aminophospholipids and their use in the preparation of pharmaceutical compositions for treating viral infections
MY155218A (en)	2015-09-30	Small molecules useful in the treatment of inflammatory disease
WO2003092624A3 (en)	2004-03-25	Use of heat shock proteins to enhance efficacy of antibody therapeutics
HK1052301A1 (zh)	2003-09-11	α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途
WO2005120557A3 (en)	2006-05-26	Inhibition of macrophage-stimulating protein receptor (ron)
ATE249835T1 (de)	2003-10-15	Immunoregulator
AU6921300A (en)	2001-03-19	Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
UA83989C2 (ru)	2008-09-10	Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
ES2092067T3 (es)	1996-11-16	Procedimiento de purificacion de una proteina altamente glicosilada.
MXPA04001986A (es)	2004-06-07	Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
AU2003240790A1 (en)	2003-12-12	Antibody peg positional isomers, compositions comprising same, and use thereof
GB0123276D0 (en)	2001-11-21	Uses of agents that bind immune-system components
WO2006122162A3 (en)	2007-08-30	Use of peptides derived from the growth factor amp-18 for the treatment of mucositis
ATE392213T1 (de)	2008-05-15	Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
WO2003099863A3 (en)	2004-02-19	Resistin binding proteins, their preparation and use
DK1299350T3 (da)	2004-12-13	Substituerede benzamider til styrket immunforsvar og behandling af kræft, infektioner og manio-depressive sygdomme
TW200635951A (en)	2006-10-16	Specific binding agents of human angiopoietin-2
WO2002092634A3 (de)	2003-10-30	Für histaminrezeptorsubklassen spezifische antikörper

Legal Events

Date	Code	Title	Description
2004-02-02	FC2A	Withdrawal, rejection or dismissal of laid open patent application